Smita Sihag1, Sergio De La Torre2, Meier Hsu3, Tamar Nobel2, Kay See Tan3, Hans Gerdes4, Pari Shah4, Manjit Bains2, David R Jones2, Daniela Molena2. 1. Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: sihags@mskcc.org. 2. Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. 3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. 4. Gastroenterology, Hepatology, and Nutrition Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Abstract
OBJECTIVE: As endoscopic approaches become more widely used to treat early-stage esophageal cancer, reliably identifying patients with less-aggressive tumors is paramount. We sought to identify risk factors for recurrence in patients with completely resected T1 esophageal adenocarcinoma. METHODS: We retrospectively analyzed a single-institutional database for all patients with completely resected pathologic T1 esophageal adenocarcinoma (1996-2016). Risk factors for recurrence were identified using competing-risk regression methods. Risk stratification was performed on the basis of known preoperative clinicopathologic factors; this model's discriminative power for overall survival was evaluated using a Cox proportional hazards model. RESULTS: Of 243 patients, 32 experienced recurrence. At a median follow-up among survivors of 4 years (range, 0.05-19 years), the 5-year cumulative incidence of recurrence was 15%, and median time to recurrence was 2 years (range, 0.26-6.13 years). On univariable analysis, submucosal invasion, N1 disease, poor differentiation, tumor length, lymphovascular invasion, and multicentricity were significantly associated with recurrence. On multivariable analysis, N1 disease (hazard ratio, 2.93; 95% confidence interval, 1.17-7.34; P = .022) and tumor length (hazard ratio, 1.44; 95% confidence interval, 1.12-1.86; P = .004) were independently associated with recurrence. Risk stratification showed that patients without lymphovascular invasion and a with median tumor length of 0.8 cm (range, 0.10-1.70 cm) had a <10% risk of recurrence and improved survival. CONCLUSIONS: Pathologic T1 tumors have a 5-year cumulative incidence of recurrence of 15%. Nodal involvement and tumor length were independent risk factors for recurrence, whereas tumors <2 cm in length without lymphovascular invasion were associated with a low risk of recurrence.
OBJECTIVE: As endoscopic approaches become more widely used to treat early-stage esophageal cancer, reliably identifying patients with less-aggressive tumors is paramount. We sought to identify risk factors for recurrence in patients with completely resected T1 esophageal adenocarcinoma. METHODS: We retrospectively analyzed a single-institutional database for all patients with completely resected pathologic T1 esophageal adenocarcinoma (1996-2016). Risk factors for recurrence were identified using competing-risk regression methods. Risk stratification was performed on the basis of known preoperative clinicopathologic factors; this model's discriminative power for overall survival was evaluated using a Cox proportional hazards model. RESULTS: Of 243 patients, 32 experienced recurrence. At a median follow-up among survivors of 4 years (range, 0.05-19 years), the 5-year cumulative incidence of recurrence was 15%, and median time to recurrence was 2 years (range, 0.26-6.13 years). On univariable analysis, submucosal invasion, N1 disease, poor differentiation, tumor length, lymphovascular invasion, and multicentricity were significantly associated with recurrence. On multivariable analysis, N1 disease (hazard ratio, 2.93; 95% confidence interval, 1.17-7.34; P = .022) and tumor length (hazard ratio, 1.44; 95% confidence interval, 1.12-1.86; P = .004) were independently associated with recurrence. Risk stratification showed that patients without lymphovascular invasion and a with median tumor length of 0.8 cm (range, 0.10-1.70 cm) had a <10% risk of recurrence and improved survival. CONCLUSIONS: Pathologic T1 tumors have a 5-year cumulative incidence of recurrence of 15%. Nodal involvement and tumor length were independent risk factors for recurrence, whereas tumors <2 cm in length without lymphovascular invasion were associated with a low risk of recurrence.
Authors: H L van Westreenen; M Westerterp; P M M Bossuyt; J Pruim; G W Sloof; J J B van Lanschot; H Groen; J Th M Plukker Journal: J Clin Oncol Date: 2004-09-15 Impact factor: 44.544
Authors: Tamar B Nobel; Arianna Barbetta; Meier Hsu; Kay See Tan; Smita Sihag; Manjit S Bains; David R Jones; Daniela Molena Journal: J Am Coll Surg Date: 2019-05-17 Impact factor: 6.113
Authors: William D Bolton; Wayne L Hofstetter; Ashleigh M Francis; Arlene M Correa; Jaffer A Ajani; Manoop S Bhutani; Jeremy Erasmus; Ritsuko Komaki; Dipen M Maru; Reza J Mehran; David C Rice; Jack A Roth; Ara A Vaporciyan; Garrett L Walsh; Stephen G Swisher Journal: J Thorac Cardiovasc Surg Date: 2009-04-09 Impact factor: 5.209
Authors: Anthony M Gamboa; Sungjin Kim; Seth D Force; Charles A Staley; Kevin E Woods; David A Kooby; Shishir K Maithel; Jennifer A Luke; Katherine M Shaffer; Sunil Dacha; Nabil F Saba; Steven A Keilin; Qiang Cai; Bassel F El-Rayes; Zhengjia Chen; Field F Willingham Journal: Cancer Date: 2016-05-03 Impact factor: 6.860
Authors: Kamran Mohiuddin; Russell Dorer; Mustapha A El Lakis; Hejin Hahn; James Speicher; Michal Hubka; Donald E Low Journal: Ann Surg Oncol Date: 2016-03-28 Impact factor: 5.344
Authors: Ermanno Ancona; Sabrina Rampado; Mauro Cassaro; Giorgio Battaglia; Alberto Ruol; Carlo Castoro; Giuseppe Portale; Francesco Cavallin; Massimo Rugge Journal: Ann Surg Oncol Date: 2008-08-26 Impact factor: 5.344
Authors: Carrie Luu; Marisa Amaral; Jason Klapman; Cynthia Harris; Khaldoun Almhanna; Sarah Hoffe; Jessica Frakes; Jose M Pimiento; Jacques P Fontaine Journal: World J Gastroenterol Date: 2017-12-14 Impact factor: 5.742